
Etrasimod
CAS No. 1206123-37-6
Etrasimod( APD334 | APD-334 | APD 334 )
Catalog No. M10751 CAS No. 1206123-37-6
Etrasimod (APD334) is a potent, selective, centrally available S1P1 receptor antagonist with β-arrestin EC50 of 6.1 nM, internalizes human S1P1 in CHO cells expressing HA tagged S1P1 with IC50 of 1.88 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 61 | Get Quote |
![]() ![]() |
5MG | 104 | Get Quote |
![]() ![]() |
10MG | 172 | Get Quote |
![]() ![]() |
25MG | 332 | Get Quote |
![]() ![]() |
50MG | 500 | Get Quote |
![]() ![]() |
100MG | 628 | Get Quote |
![]() ![]() |
200MG | 895 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameEtrasimod
-
NoteResearch use only, not for human use.
-
Brief DescriptionEtrasimod (APD334) is a potent, selective, centrally available S1P1 receptor antagonist with β-arrestin EC50 of 6.1 nM, internalizes human S1P1 in CHO cells expressing HA tagged S1P1 with IC50 of 1.88 nM.
-
DescriptionEtrasimod (APD334) is a potent, selective, centrally available S1P1 receptor antagonist with β-arrestin EC50 of 6.1 nM, internalizes human S1P1 in CHO cells expressing HA tagged S1P1 with IC50 of 1.88 nM; produces robust lymphocyte lowering effect (IC50=0.1 uM in mice), shows effectivity in mouse experimental autoimmune encephalomyelitis (EAE) model of MS and a rat collagen induced arthritis (CIA) model, orally active.Irritable Bowel Syndrome Phase 2 Clinical(In Vitro):APD334 is a structurally novel, selective, functional antagonist of S1P1. In CHO cells expressing HA tagged S1P1, APD334 is found to have an IC50 value of 1.88 nM. Moderate agonism at human S1P4 and S1P5 is observed but is reduced relative to S1P1, both in terms of potency and efficacy. APD334 is devoid of any agonism or antagonism at human S1P2 and S1P3. APD334 achieves good central exposure following oral dosing and possesses a favorable pharmacokinetic profile in multiple preclinical species. S1P1 activity is maintained in mice (EC50=0.44 nM), rats (EC50=0.32 nM), dogs (EC50=0.34 nM) and monkeys (EC50=0.32 nM).(In Vivo):APD334 has a relatively low systemic clearance (<4% of hepatic blood flow) and high Cmax across all species. In both dog and monkey a significant decrease in volume of distribution (Vss) is observed relative to rodent. Oral bioavailability is in the range of 40–100%, and the terminal phase half-life varied from 6 h in monkey, to as long as 29 h in dog. Rat and monkey t1/2 values for siponimod (another S1P1 modulator currently in human trials) have been disclosed and are 6 and 19 h, respectively.
-
In Vitro——
-
In Vivo——
-
SynonymsAPD334 | APD-334 | APD 334
-
PathwayGPCR/G Protein
-
TargetLysophospholipid Receptor
-
RecptorLysophospholipid Receptor
-
Research AreaOther Indications
-
IndicationIrritable Bowel Syndrome
Chemical Information
-
CAS Number1206123-37-6
-
Formula Weight457.4847
-
Molecular FormulaC26H26F3NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 28 mg/mL
-
SMILESC1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F
-
Chemical NameCyclopent[b]indole-3-acetic acid, 7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydro-, (3R)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Buzard DJ, et al. ACS Med Chem Lett. 2014 Nov 4;5(12):1313-7.
2. Peyrin-Biroulet L, et al. Autoimmun Rev. 2017 May;16(5):495-503.
3. Nielsen OH, et al. Expert Opin Investig Drugs. 2016 Jun;25(6):709-18.
molnova catalog



related products
-
BMS-986020
BMS-986020 (BMS986020, AM-152) is a potent, selective, orally available LPA1 receptor antagonist for treating idiopathic pulmonary fibrosis.
-
Mocravimod
A synthetic immunosuppressant that functions as a S1P1 receptor agonist.
-
Amiselimod hydrochlo...
A novel prodrug S1P receptor modulator lacking S1P3 receptor agonism to avoid bradycardia associated with fingolimod and other S1P receptor modulators.